Horizon Pharma (NASDAQ:HZNP) received a $17.00 price objective from Cantor Fitzgerald in a research report issued on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 13.18% from the stock’s current price.
HZNP has been the topic of a number of other reports. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma and gave the stock a “buy” rating in a report on Sunday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of Horizon Pharma in a report on Sunday, October 22nd. ValuEngine upgraded Horizon Pharma from a “hold” rating to a “buy” rating in a report on Monday, October 16th. Cowen reaffirmed a “buy” rating on shares of Horizon Pharma in a research report on Thursday, September 28th. Finally, Goldman Sachs Group assumed coverage on Horizon Pharma in a research report on Thursday, September 28th. They issued a “buy” rating and a $16.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the stock. Horizon Pharma has an average rating of “Buy” and a consensus price target of $18.75.
Shares of Horizon Pharma (HZNP) traded up $0.08 during midday trading on Wednesday, hitting $15.02. The company had a trading volume of 1,001,754 shares, compared to its average volume of 3,337,835. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89. The firm has a market cap of $2,440.00, a PE ratio of -4.94, a price-to-earnings-growth ratio of 1.26 and a beta of 1.31. Horizon Pharma has a twelve month low of $9.45 and a twelve month high of $18.31.
Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can boosted its position in Horizon Pharma by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Horizon Pharma by 82.8% during the second quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 69,626 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in Horizon Pharma by 2,170.0% during the second quarter. Canada Pension Plan Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 21,700 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Horizon Pharma by 12.8% during the second quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 1,466 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Horizon Pharma by 3.4% during the second quarter. Rhumbline Advisers now owns 210,843 shares of the biopharmaceutical company’s stock valued at $2,503,000 after purchasing an additional 6,871 shares during the last quarter. 86.58% of the stock is owned by institutional investors and hedge funds.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
